Axoltis’ Phase II ALS trial fails; company points to exploratory endpoints
Axoltis Pharma is undertaking additional analysis of its Phase II amyotrophic lateral sclerosis (ALS) trial after it failed to meet…
News
Syntis Bio announces Phase I/Ib data for SYNT-101 in obesity
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Trial run: FDA launches pilot for expedited INDs
Vera set up for full approval for Trutakna in IgAN with Phase III win
Agentic AI trust gap slowing healthcare provider adoption, survey reveals
Definium tees up regulatory submission for psychedelic on Phase III hat trick
BioNTech and OncoC4 report median OS data from RESERVE-003 Phase III trial
